Breast Cancer

Official Title: T-DM1 and Tucatinib Compared With T-DM1 Alone In Preventing Relapses In People With High Risk Her2-Positive Breast Cancer

Study Purpose: To compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.

Status: Recruiting

Official Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy  

Study Purpose: To evaluate whether observation results in a non-inferior recurrence free survival compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pathological complete response after neoadjuvant chemotherapy with pembrolizumab 

Status: Recruiting

Official Title:  Breast Cancer Registry

Study Purpose: BCCR is a unique resource for the collection and management of cancer and health-related data.

Status: Recruiting

Official Title: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Study Purpose: This study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. 

Status: Recruiting

Official Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

Status: Recruiting

Official Title: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

Study Purpose: Evaluate the correlation of Minimal Residual Disease detection by NeXT Personal CTA (a molecular test) to pathological Complete Response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC)

Status: Recruiting